BioSpace News Archive

NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of Herceptin® (trastuzumab), has successfully met all primary and secondary endpoints in a Phase I clinical trial.

Global Marketing Agency Awarded for Content Excellence and Industry Reach Alongside the Biggest Names in Healthcare

The nation’s most comprehensive care collaboration platform launches two new products and enhancements to its product suite ahead of highly-anticipated E-notifications Conditions of Participation rule [05-December-2019] BOSTON , Dec. 5, 2019 /PRNewswire/ -- PatientPing, the nation’s leading care collaboration network, today announced the launch of two new products, Ca

Arecor Limited announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.

Applied DNA Sciences, Inc., announced it plans to release financial results for its fiscal 2019 fourth quarter ended September 30, 2019 after market close on Thursday, December 12, 2019.

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis, showed dramatic superiority over Gefapixant, Merck’s lead phase 3 trial drug, in a well accepted acute cough in-vivo animal study.

In 2018, there were 2,782 organ transplant procedures performed in Canada, according to the latest information published by the Canadian Institute for Health Information.

ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory body

Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019

CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced today a corporate update and reported financial results for the third quarter and the nine months ended September 30, 2019.